Athira Pharma, Inc (ATHA) recently announced that it has dosed the last patient in the phase II/III LIFT-AD study, which is evaluating its pipeline candidate, fosgonimeton for the treatment of mild-to-moderate Alzheimer’s disease (AD). Shares of the company were up 29.4%, following the announcement of the news.The LIFT-AD study evaluates once-daily fosgonimeton (40 mg) subcutaneous injection versus placebo over a treatment period of 26 weeks in mild-to-moderate AD patients. The study is designed to assess t ...